Change in biomarkers of type-2 inflammation following severe exacerbations of asthma. Semprini, R., Shortt, N., Ebmeier, S., Semprini, A., Varughese, R., Holweg, C. T J, Matthews, J. G, Fingleton, J., Weatherall, M., Beasley, R., & Braithwaite, I. Thorax, 74(1):95–98, January, 2019. Number: 1![Change in biomarkers of type-2 inflammation following severe exacerbations of asthma [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10 9 /L, p\textless0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p\textless0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p\textless0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma. Trial registration number Post-results; The Australia New Zealand Trial Registry, \textgreaterACTRN12614000443695.
@article{semprini_change_2019,
title = {Change in biomarkers of type-2 inflammation following severe exacerbations of asthma},
volume = {74},
issn = {0040-6376, 1468-3296},
url = {http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2018-211657},
doi = {10.1136/thoraxjnl-2018-211657},
abstract = {We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10
9
/L, p{\textless}0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p{\textless}0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p{\textless}0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma.
Trial registration number
Post-results; The Australia New Zealand Trial Registry, {\textgreater}ACTRN12614000443695.},
language = {en},
number = {1},
urldate = {2020-08-23},
journal = {Thorax},
author = {Semprini, Ruth and Shortt, Nick and Ebmeier, Stefan and Semprini, Alex and Varughese, Rachel and Holweg, Cecile T J and Matthews, John G and Fingleton, James and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},
month = jan,
year = {2019},
note = {Number: 1},
pages = {95--98},
}
Downloads: 0
{"_id":"5mxRJWb2HwFXF9cAu","bibbaseid":"semprini-shortt-ebmeier-semprini-varughese-holweg-matthews-fingleton-etal-changeinbiomarkersoftype2inflammationfollowingsevereexacerbationsofasthma-2019","authorIDs":["N3obYpqrxxsH3YJWN","XpthFsNinuhKsH7pw","aAr8RG55mgpbTJNwL","fkXvTs3mckAQTCNLq","reqj5nKrqAA7Ywbrs","wqgwP5AoWzbZ24aoX"],"author_short":["Semprini, R.","Shortt, N.","Ebmeier, S.","Semprini, A.","Varughese, R.","Holweg, C. T J","Matthews, J. G","Fingleton, J.","Weatherall, M.","Beasley, R.","Braithwaite, I."],"bibdata":{"bibtype":"article","type":"article","title":"Change in biomarkers of type-2 inflammation following severe exacerbations of asthma","volume":"74","issn":"0040-6376, 1468-3296","url":"http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2018-211657","doi":"10.1136/thoraxjnl-2018-211657","abstract":"We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10 9 /L, p\\textless0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p\\textless0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p\\textless0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma. Trial registration number Post-results; The Australia New Zealand Trial Registry, \\textgreaterACTRN12614000443695.","language":"en","number":"1","urldate":"2020-08-23","journal":"Thorax","author":[{"propositions":[],"lastnames":["Semprini"],"firstnames":["Ruth"],"suffixes":[]},{"propositions":[],"lastnames":["Shortt"],"firstnames":["Nick"],"suffixes":[]},{"propositions":[],"lastnames":["Ebmeier"],"firstnames":["Stefan"],"suffixes":[]},{"propositions":[],"lastnames":["Semprini"],"firstnames":["Alex"],"suffixes":[]},{"propositions":[],"lastnames":["Varughese"],"firstnames":["Rachel"],"suffixes":[]},{"propositions":[],"lastnames":["Holweg"],"firstnames":["Cecile","T","J"],"suffixes":[]},{"propositions":[],"lastnames":["Matthews"],"firstnames":["John","G"],"suffixes":[]},{"propositions":[],"lastnames":["Fingleton"],"firstnames":["James"],"suffixes":[]},{"propositions":[],"lastnames":["Weatherall"],"firstnames":["Mark"],"suffixes":[]},{"propositions":[],"lastnames":["Beasley"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Braithwaite"],"firstnames":["Irene"],"suffixes":[]}],"month":"January","year":"2019","note":"Number: 1","pages":"95–98","bibtex":"@article{semprini_change_2019,\n\ttitle = {Change in biomarkers of type-2 inflammation following severe exacerbations of asthma},\n\tvolume = {74},\n\tissn = {0040-6376, 1468-3296},\n\turl = {http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2018-211657},\n\tdoi = {10.1136/thoraxjnl-2018-211657},\n\tabstract = {We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10\n 9\n /L, p{\\textless}0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p{\\textless}0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p{\\textless}0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma.\n \n \n Trial registration number\n Post-results; The Australia New Zealand Trial Registry, {\\textgreater}ACTRN12614000443695.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {Thorax},\n\tauthor = {Semprini, Ruth and Shortt, Nick and Ebmeier, Stefan and Semprini, Alex and Varughese, Rachel and Holweg, Cecile T J and Matthews, John G and Fingleton, James and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},\n\tmonth = jan,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {95--98},\n}\n\n","author_short":["Semprini, R.","Shortt, N.","Ebmeier, S.","Semprini, A.","Varughese, R.","Holweg, C. T J","Matthews, J. G","Fingleton, J.","Weatherall, M.","Beasley, R.","Braithwaite, I."],"key":"semprini_change_2019","id":"semprini_change_2019","bibbaseid":"semprini-shortt-ebmeier-semprini-varughese-holweg-matthews-fingleton-etal-changeinbiomarkersoftype2inflammationfollowingsevereexacerbationsofasthma-2019","role":"author","urls":{"Paper":"http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2018-211657"},"metadata":{"authorlinks":{"beasley, r":"https://www.mrinz.ac.nz/"}},"downloads":0},"bibtype":"article","creationDate":"2019-06-09T22:34:08.051Z","downloads":0,"keywords":[],"search_terms":["change","biomarkers","type","inflammation","following","severe","exacerbations","asthma","semprini","shortt","ebmeier","semprini","varughese","holweg","matthews","fingleton","weatherall","beasley","braithwaite"],"title":"Change in biomarkers of type-2 inflammation following severe exacerbations of asthma","year":2019,"biburl":"https://api.zotero.org/users/6607533/collections/EUK4Z2Y3/items?key=hGXLq241MCQA3ow7rlTIV2gY&format=bibtex&limit=100","dataSources":["g6GzqSeiNQrL4uwxq","2gjE2Mtkr96KKZopW","ya2CyA73rpZseyrZ8","hRAfAvmcA3uAsD4SS","477QN6SvdKQPLJFBK","mxqxyoTcgN4SAfkJ8","2252seNhipfTmjEBQ"]}